Scientific Research Publishing

American Journal of Analytical Chemistry, 2026, 17(7), 269-302
https://www.scirp.org/journal/ajac
ISSN Online: 2156-8278
ISSN Print: 2156-8251

Analytical Method Validation and Forced Degradation Studies of Drug Substances and Drug Products: An Overview of Principles, Regulatory Guidance, and Current Practices

Sai Krishna Bompelliwar[1*], Ravi Teja Meduri[1], Mohit Chintakindi Bhasker[2], Rasheed Babu Shaik[1], Abhishek Mishra[1]

[1]MedPharm Manufacturing Services LLC, Durham, NC, USA
[2]ARL Bio Pharma, Oklahoma City, OK, USA
Email: *bompelliwarsaikrishna@gmail.com

How to cite this paper: Bompelliwar, S.K., Meduri, R.T., Bhasker, M.C., Shaik, R.B. and Mishra, A. (2026) Analytical Method Validation and Forced Degradation Studies of Drug Substances and Drug Products: An Overview of Principles, Regulatory Guidance, and Current Practices. *American Journal of Analytical Chemistry*, **17**, 269-302.
https://doi.org/10.4236/ajac.2026.177016

Received: June 18, 2026
Accepted: July 27, 2026
Published: July 30, 2026

Abstract

The development of validated stability-indicating analytical methods is a cornerstone of pharmaceutical development and quality assurance. Forced degradation (stress testing) studies, as recommended by international regulatory guidelines, provide the experimental foundation for characterizing drug substance and drug product degradation behavior, establishing degradation pathways, identifying and structurally elucidating degradation products, and demonstrating analytical method specificity. Despite a well-established regulatory framework centered on the ICH (International Council for Harmonisation) Q1 series, Q2(R2), Q3A/B, and the emerging Q14 guideline, consolidated overviews of methodology, regulatory expectations, and current analytical practice remain limited in scope. This overview examines the published literature on forced degradation study design, degradation chemistry, analytical techniques for degradant characterization, and ICH Q2(R2)-compliant method validation as applied to pharmaceutical drug substances and drug products, providing an integrated, regulation-aligned reference framework applicable to small-molecule drug substances and drug products. A structured literature search was conducted, and regulatory guidance documents from ICH, FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization) were reviewed. Sources were selected based on their relevance to forced degradation methodology, degradant characterization, and analytical method validation for pharmaceutical drug substances and drug

products. Pharmaceutical drug substances and drug products are susceptible to hydrolytic, oxidative, photolytic, thermolytic, and humidity-induced degradation under stress conditions. The commonly accepted 5% - 20% degradation target is generally considered sufficient to generate primary degradants without secondary degradation artefacts. Reversed-phase HPLC (RP-HPLC) coupled with photodiode array (PDA) detection remains the predominant analytical platform; hyphenated techniques including LC-MS/MS, LC-HRMS, and NMR are frequently employed for degradant identity confirmation above ICH Q3B(R2) reporting, identification, or qualification thresholds. Mass balance in the range of 95% - 105%, combined with full ICH Q2(R2) validation covering specificity, linearity, accuracy, precision, limit of detection (LOD), limit of quantitation (LOQ), and robustness, is widely regarded as the current standard for demonstrating the stability-indicating character of an analytical method. This overview provides a comprehensive methodological framework for forced degradation and analytical method validation of small-molecule drug substances and drug products, encompassing regulatory convergence and divergence across global jurisdictions, with discussion of the ongoing transition toward ICH Q14-aligned analytical procedure lifecycle management. The framework is intended as a practical reference for pharmaceutical scientists and regulatory affairs professionals engaged in drug substance and drug product development and regulatory submission activities. Biological products are not covered, as their stability assessment and forced degradation studies require specialized analytical strategies that are beyond the scope of this overview.

Keywords

Forced Degradation, Stress Testing, Analytical Method Validation, Stability-Indicating Method, RP-HPLC, ICH Guidelines, Drug Substance, Drug Product, Mass Balance, Degradation Products, Regulatory Submission, ICH Q2 and ICH Q14, Pharmaceutical Quality Assurance

1. Introduction

The global pharmaceutical industry operates under a quality assurance paradigm that requires every marketed drug substance and drug product to demonstrably maintain its therapeutic efficacy, safety, and physicochemical integrity throughout its defined shelf life. Central to this paradigm is the analytical characterization of drug product stability, specifically, the identification, quantitation, and structural elucidation of degradation products that may arise during the manufacturing process, long-term storage, or patient-use conditions. Stability-indicating analytical methods capable of simultaneously quantifying the drug substance and any degradation products without mutual interference form the analytical cornerstone of pharmaceutical stability programs. Forced degradation studies, also referred to as stress testing or stress degradation studies, are conducted by deliberately subjecting the drug substance (DS), drug product (DP), and placebo to phys-

icochemical stress conditions more extreme than those used in accelerated stability testing. These conditions, typically acid and alkali hydrolysis, oxidative stress, thermal exposure, photolytic irradiation, and humid/thermal combined stress, are designed to accelerate the degradation processes likely to occur over the product's shelf life, within a controlled and scientifically tractable time frame. The resulting degradation products (degradants) are characterized, and the study outcomes serve multiple scientific and regulatory purposes. From a scientific perspective, forced degradation studies provide mechanistic insights into the intrinsic stability of the active pharmaceutical ingredient within its formulation matrix. These insights inform formulation design decisions (e.g., choice of excipients, antioxidant inclusion, pH adjustment of liquid formulations), manufacturing process development (e.g., handling under inert atmosphere, light exclusion), and primary packaging selection (e.g., moisture barrier, light-protective materials) [1]-[6]. From a regulatory perspective, forced degradation studies are recommended by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines Q1A(R2), Q1B, and Q2(R2) as primary evidence that the analytical method used for quality control and stability testing is stability-indicating, *i.e.*, that it can detect and quantify degradants without interference from the parent drug, excipients and other degradation products [7]-[9]. The regulatory landscape governing forced degradation and method validation has evolved considerably since the initial ICH Q1 guidelines in the mid-1990s. The forthcoming ICH Q2(R2) revision, together with the new ICH Q14 guideline on Analytical Procedure Development, signals a fundamental shift from a pass/fail validation paradigm to a lifecycle management approach, in which method performance is continuously monitored and the method's design space (Method Operable Design Region, MODR) is prospectively defined through Quality by Design (QbD) principles [10]-[13]. This regulatory evolution necessitates that pharmaceutical analytical scientists update both their methodological practice and their documentation strategy. Despite extensive primary literature on forced degradation of specific drug molecules, comprehensive reviews that integrate forced degradation methodology with analytical validation science, critically appraise the global regulatory framework, and address current analytical technology and lifecycle management approaches in a drug-generic manner are limited. This review addresses that gap, providing a consolidated and critically evaluated reference for pharmaceutical scientists and regulatory professionals engaged in drug product development and regulatory submission activities.

2. Review Methodology

This review was conducted using a structured literature search to identify publications related to stability-indicating analytical methods, forced degradation studies, impurity profiling, degradation product identification, and regulatory requirements. Electronic databases, including PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar, were searched for articles published between January 2000 and March 2026. Regulatory guidance documents from the ICH, United States

Pharmacopeia (USP), European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA) were also included.

The search strategy employed combinations of the following keywords: "stability-indicating method", "forced degradation", "stress testing", "degradation products", "impurity profiling", "method validation", "ICH Q1A", "ICH Q2", "ICH Q3A", "ICH Q3B", "LC-MS", "HRMS", "NMR", and "pharmaceutical analysis". Boolean operators (AND/OR) were used to refine the search. Studies were included if they 1) discussed stability-indicating analytical methods or degradation product characterization, 2) described analytical techniques applicable to pharmaceutical quality assessment, or 3) reported regulatory recommendations relevant to degradation studies. Editorials, conference abstracts without sufficient technical detail, non-English publications, and studies unrelated to pharmaceutical stability assessment were excluded. Titles and abstracts were screened for relevance, followed by full-text evaluation of eligible publications. Duplicate records were removed before final inclusion. The selected literature was synthesized narratively to summarize current analytical strategies for analytical method validation and forced degradation studies.

3. Regulatory Framework for Forced Degradation and Analytical Method Validation

3.1. Overview of ICH Guidelines

The ICH Quality guidelines provide the primary international regulatory framework for forced degradation studies and analytical method validation. The core guidelines directly relevant to this review are: ICH Q1A(R2) Stability Testing of New Drug Substances and Products; ICH Q1B Photostability Testing; ICH Q2(R2) Validation of Analytical Procedures; ICH Q3A(R2)/Q3B(R2) Impurities in New Drug Substances and Drug Products [14] [15]; ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products (Chemical Substance) [16]; ICH M4Q(R1) CTD for Quality (Module 3 format) [17]; and the emerging ICH Q14 Analytical Procedure Development.

3.2. ICH Q1A(R2) Stability Testing

ICH Q1A(R2) recommends that stress testing be conducted to establish the inherent stability characteristics of a drug substance and products, to identify likely degradation products, to demonstrate the specificity of the analytical method, and to support the selection of packaging materials and storage conditions. Stress conditions typically include the effect of: 1) elevated temperatures in 10˚C increments above the accelerated condition; 2) high humidity (typically ≥75% RH at or above room temperature); 3) hydrolysis across a wide pH range (acid, base, neutral); 4) susceptibility to oxidation; and 5) photolysis, as directed by ICH Q1B. Stress testing is typically performed on representative batches of drug substance, drug product, and placebo where appropriate to facilitate assessment of degradation products. The guideline indicates that degradation products observed exclusively un-

der stress conditions and not during accelerated or long-term stability conditions may not require routine monitoring, but their formation and characterization must be documented. The decision tree for the data evaluation for Shelf-life estimation for Drug Substance and Products is presented in Figure 1.



Figure 1. Decision tree for data evaluation for shelf-life estimation for drug substance and products.

3.3. ICH Q1B Photostability

ICH Q1B recommends confirmatory photostability testing as a standard requirement for all new drug substances and drug products, with forced photodegradation studies as an additional investigation tool. The minimum light exposure for confirmatory studies is ≥1.2 × 10^6 lux·h (visible) and ≥200 Wh/m^2 (UV), using either a D65 artificial daylight fluorescent source (Option 1) or a cool white fluorescent lamp combined with a near-UV fluorescent lamp (Option 2). Drug products are typically tested sequentially: first without primary packaging, then in the immediate container, and finally in the marketing package. Samples must be protected from moisture and temperature effects unrelated to photolysis. A decision flow chart for photostability testing for drug products is presented in Figure 2.



Figure 2. Decision flow chart for photostability testing of drug product.

3.4. ICH Q2(R2) and the Emerging Q2(R2)/Q14 Framework

ICH Q2(R2) defines the validation characteristics applicable to different types of analytical procedures. For stability-indicating assay and related substances determination, the required characteristics are specificity, linearity, range, accuracy, precision (repeatability and intermediate precision), LOQ, LOD, robustness, and solution stability in addition to the forced degradation studies. Critically, ICH Q2(R2) permits the use of samples generated from forced degradation studies as impurity surrogates in specificity demonstrations when authentic impurity reference standards are not available. The forthcoming ICH Q2(R2) and Q14 guidelines further advance the toward lifecycle management. Under ICH Q14, an Analytical Target Profile (ATP) is defined as a prospective statement of the quality attributes the method must measure and the performance requirements it must achieve. Method development is then guided by Design of Experiment (DOE) to map the Method Operable Design Region (MODR), analogous to the design space concept in ICH Q8 for pharmaceutical development. Analytical procedure control strategies are established to ensure performance remains within the MODR throughout the product lifecycle. Regulatory submissions incorporating an ATP and MODR may facilitate enhanced change management approaches, enabling certain post-approval analytical changes without a prior approval supplement. An ICH Q14-aligned analytical procedure lifecycle management framework for stability-indicating methods is presented in Figure 3.

3.5. ICH Q3A(R2)/Q3B(R2) Impurity Thresholds

The reporting, identification, and qualification thresholds specified in ICH Q3A(R2) and Q3B(R2) directly influence the required sensitivity (LOQ), impurity



Figure 3. ICH Q14-aligned analytical procedure life cycle management for stability indicating method.

characterization strategy, and toxicological evaluation requirements associated with a stability-indicating method. Table 1 summarizes the applicable thresholds as a function of drug substance and drug product maximum daily dose. For genotoxic (mutagenic) impurities and degradants, ICH M7(R2) describes a Threshold of Toxicological Concern (TTC) of 1.5 μg/day for lifetime exposure, and provides a risk-based framework for assessment, including structural alert screening and, where appropriate, genotoxicity testing or application of the staged TTC approach [18].

Table 1. ICH impurity reporting, identification, and qualification thresholds for drug substances and drug products.

Category	Maximum Daily Dose[1]	Reporting Threshold	Identification Threshold		Qualification Threshold	
Drug Substance	≤2 g/day	0.05%	0.10% or 1.0 mg/day		0.15% or 1.0 mg/day	
	>2 g/day	0.03%	0.05%		0.05%	
Drug Product	≤1 g/day	0.10%	<1 mg	1.0% or 5 μg TDI	<10 mg	1.0% or 50 μg TDI
			1 mg - 10 mg	0.5% or 20 μg TDI	10 mg - 100 mg	0.5% or 200 μg TDI
	>1 g/day	0.05%	10 mg - 2 g	0.2% or 2 mg TDI	100 mg - 2 g	0.2% or 3 mg TDI
			>2 g	0.10%	>2 g	0.15%

[1]The amount of drug substance administered per day; TDI = total daily intake.

4. Forced Degradation Study Design

4.1. Study Objectives and Scope

A forced degradation program for a pharmaceutical drug substance and drug product typically pursues following objectives [19]-[29]:

1) To evaluate the chemical stability of the drug substance and drug product under deliberately intensified stress conditions, including acid and base hydrolysis, oxidative, photolytic, and thermal stress, per ICH Q1A(R2).

2) To identify and characterize potential degradation products formed during

stress testing, including structural elucidation of uncharacterized degradants using appropriate techniques such as LC-MS/MS and NMR spectroscopy as appropriate, in compliance with ICH Q1A(R2) and Q1B guidelines.

3) To develop a robust, specific, and sensitive stability-indicating analytical method (typically RP-HPLC or UPLC) capable of separating the drug substance from its degradation products, with peak purity confirmed by photodiode array (PDA) detection and, where required, mass spectrometric analysis.

4) To assess the extent of degradation under each stress condition and quantify the percentage of drug substance remaining after exposure, typically targeting 5% - 20% degradation to generate meaningful degradation products while minimizing secondary interactions.

5) To ensure mass balance by accounting for the total percentage of the drug substance and all its degradation products under each stress condition, with a widely accepted range of 95% - 105%.

6) To provide scientific data supporting the selection of appropriate packaging materials, storage conditions, and shelf-life estimates, and to assist in the development of formulation strategies by identifying degradation-promoting conditions to be avoided during manufacturing and storage.

7) To fulfil regulatory requirements and provide supporting data for Investigational New Drug (IND) applications, New Drug Applications (NDAs), and Abbreviated New Drug Applications (ANDAs).

8) To support establishment and justification of acceptance criteria for impurity limits and degradation thresholds in accordance with ICH Q3A(R2) and Q3B(R2) guidelines.

9) To generate reliable and reproducible stability data that supports the overall quality, safety, and efficacy of the pharmaceutical product throughout its intended shelf life.

Forced degradation studies are commonly performed on three matrices: 1) drug substance alone (to characterize intrinsic DS degradation); 2) drug product (to account for drug-excipient interactions and matrix-specific degradation); and 3) a placebo preparation (formulation without API but the same excipient composition as the drug product) to identify excipient-derived peaks that might otherwise be misattributed to drug degradants. The analytical concentration employed in forced degradation experiments should be identical to that of the intended quality control method.

4.2. Degradation Target and Stress Intensity

A widely accepted industry target for forced degradation is 5% - 20% loss of the parent compound relative to the unstressed control, as this range generates primary degradants in detectable and quantifiable quantities without inducing secondary degradation, or the over-degradation of primary degradants into further products that would be toxicologically and analytically irrelevant to real shelf-life scenarios. There is no prescriptive regulatory requirement specifying the exact

percentage in ICH Q1A(R2). In case of stable molecules, percent net degradation may be difficult to achieve as per acceptance criteria. Hence, based on the experiments, study can be concluded and summary of the experiments shall be documented. For multi-drug product placebo with different formulations containing one drug substance, each shall be subjected to forced degradation. Stress intensity should be escalated stepwise (e.g., increasing acid concentration from 0.01 M to 1.0 M, or temperature from 40˚C to 80˚C) rather than applying maximal conditions immediately, to avoid over-degradation and secondary product formation. Time-course samples (e.g., at 1, 2, 4, 8, 24, 48 h for hydrolysis) are useful for identifying the onset of secondary degradation and selecting appropriate exposure endpoints. At the first time point exhibiting <20% degradation, the sample should be designated as the final forced degradation sample.

4.3. Recommended Stress Conditions

Table 2 summarizes the recommended stress conditions, encompassing ICH Q1A(R2) and Q1B requirements, and current best-practice literature parameters.

Table 2. Recommended forced degradation stress conditions for pharmaceutical drug substances and drug products.

Stress Type	Conditions Applied	Duration	Primary Degradation Pathway
Acid Hydrolysis	0.1 - 1.0 M HCl; 25˚C - 80˚C	1 - 48 h	Ester/amide hydrolysis; ring opening
Alkaline Hydrolysis	0.1 - 1.0 M NaOH; 25˚C - 80˚C	1 - 48 h	Saponification; nucleophilic substitution
Neutral Hydrolysis	Water; 60˚C - 80˚C	24 - 72 h	pH-independent bond cleavage
Oxidative	3% or 30% H_2O_2 (v/v); room temp.	6 - 48 h	N-/S-oxidation; peroxide addition
Thermal (Dry Heat)	60˚C - 105˚C; dry oven	3 - 14 days	Pyrolysis; dehydration; cyclisation
Photolytic (Visible)	ICH Q1B Option 2: ≥1.2×10^6 lux·h	Controlled	Photo-oxidation; E/Z isomerization
Photolytic (UV)	ICH Q1B Option 2: ≥200 Wh/m^2	Controlled	Bond homolysis; radical reactions
Humid/Thermal	40˚C/75% RH; open dish	2 - 4 weeks	Moisture-catalyzed hydrolysis

H_2O_2 = hydrogen peroxide; RH = relative humidity; lux·h = lux hours; Wh/m^2 = watt-hours per square meter.

4.4. Degradation Chemistry: Principal Pathways

4.4.1. Hydrolytic Degradation

Hydrolytic degradation is the most prevalent pathway for small-molecule drug substances and drug products in aqueous or solid dosage form matrices. It proceeds by nucleophilic addition of water to electrophilic centers, principally ester, lactone, amide, lactam, carbamate, carbonate, and imine (Schiff base) functional groups. Acid-catalysed hydrolysis proceeds via protonation of the leaving group (specific acid catalysis), while alkali-catalysed hydrolysis proceeds via hydroxide-ion attack at the carbonyl carbon (specific base catalysis). General acid/base catalysis by buffer species can also contribute to solution formulations, necessitating evaluation across a range of buffer concentrations as well as pH values [25].

4.4.2. Oxidative Degradation

Oxidative degradation proceeds through two principal mechanisms: autoxidation

(radical-chain mechanisms initiated by reactive oxygen species) and direct oxidation by electrophilic oxidants. Nucleophilic centers susceptible to oxidation include tertiary amines (yielding N-oxides), thioethers (yielding sulfoxides and sulfones), alcohols (to aldehydes or carboxylic acids), aldehydes (to carboxylic acids), and electron-rich aromatic rings (hydroxylation). The use of peroxide-based stress (e.g., H_2O_2, representing nucleophilic oxidation) provides a comprehensive assessment of oxidative susceptibility; However, peroxide stress may not fully represent all oxidative degradation pathways encountered during product storage. Trace metal contaminants from excipients, packaging, or manufacturing equipment can catalyze oxidation and must be considered in formulation development [26].

4.4.3. Photolytic Degradation

Photolytic (photochemical) degradation is initiated by absorption of UV or visible radiation, generating electronically excited states that either directly react (homolytic bond cleavage, isomerization, cyclisation) or transfer energy to molecular oxygen to form singlet oxygen (Type II photosensitization), which subsequently oxidizes nucleophilic sites. Photolytic degradants are often structurally related to oxidative degradation pathways and may include N-oxides, hydroxylated products, and dimer/adduct formation in drug-excipient matrices. A key feature of photodegradation is its surface-sensitivity in solid dosage forms: tablet coating, pigmentation, and excipient photoprotection can markedly attenuate photolytic degradation of the API.

4.4.4. Thermal and Humidity-Induced Degradation

Thermal degradation under dry heat conditions typically involves elimination reactions (dehydration, decarboxylation), cyclisation, and pyrolysis of thermally labile bonds. The Arrhenius equation governs temperature dependence of the rate constant, enabling extrapolation of shelf-life predictions from accelerated data. This equation shows that the reaction rate increases exponentially with increasing temperature because more molecules possess sufficient energy to overcome the activation energy barrier.

$$k = A \cdot \exp\left(-\frac{E_a}{RT}\right) \tag{1}$$

where k = rate constant, A = frequency factor, E_a = activation energy, R = universal gas constant, T = absolute temperature (K).

In the presence of moisture (humid/thermal conditions), hydrolysis is accelerated in nominally solid dosage forms because absorbed water plasticizes the amorphous fraction of the solid matrix, facilitating molecular mobility and increasing the apparent hydrolysis rate. For hygroscopic drug substances or those in amorphous form, humid/thermal degradation represents a critical stability risk.

4.4.5. Drug-Excipient Interaction Products

Interaction between the drug substance and formulation excipients under stress

conditions can generate degradation products not observed from the drug substance alone. Well-characterized examples include: Maillard reaction adducts between primary or secondary amine drugs and reducing sugars (lactose, glucose) in tablet excipients; ester formation between hydroxyl-containing drugs and organic acid excipients (e.g., stearic acid from magnesium stearate); and peroxide-mediated oxidation of drugs by peroxides present in polysorbates, polyethylene glycols, and hydroxypropyl methylcellulose. Placebo control studies are highly valuable for identifying such excipient-interaction degradants [27]. Pharmaceutical degradation mechanism is presented in Figure 4.



Figure 4. Pharmaceutical degradation mechanism.

4.5. Analytical Techniques for Degradant Characterization

Table 3 provides a comprehensive summary of analytical techniques employed in forced degradation studies, their application, regulatory relevance, advantages, and limitations. A tiered, decision-tree approach beginning with HPLC-PDA for initial detection and peak purity, followed by LC-MS/MS for identity confirmation, and progressing to HRMS and NMR for definitive structure elucidation, where warranted by regulatory thresholds, is widely regarded as the current best practice.

Table 3. Analytical techniques used in forced degradation studies: applications, regulatory relevance, and comparative evaluation.

Technique	Application in FD Studies	Advantages	Limitations
RP-HPLC + UV	Separation, assay, impurity quantitation	Robust; widely accepted; easy transfer	Cannot confirm identity; limited for chromophore-free species
RP-HPLC + PDA	Peak purity; spectral profiling	Real-time spectral acquisition; library matching	Cannot distinguish co-eluters with identical spectra
HPLC + ELSD/CAD	Detection of chromophore-free degradants	Universal detection; near-equimolar response	Poor sensitivity vs. UV; not suitable for volatile analytes
LC-ESI-MS (single quad)	Molecular ion confirmation (MH^+, $[M+Na]^+$)	Rapid identity screening; high sensitivity	No structural fragmentation; adduct complexity

Continued

LC-MS/MS (triple quad)	Structural fragmentation; targeted quantitation	Definitive fragmentation patterns; high selectivity	Reference fragmentation needed; matrix suppression
LC-HRMS (Q-TOF, Orbitrap)	Exact mass; molecular formula determination	Sub-ppm mass accuracy; de novo formula assignment	High cost; complex data interpretation
NMR ^{1}H, ^{13}C, 2D	Definitive structure elucidation of isolated degradants	Gold standard for structure; stereo-/regiochemistry	Requires mg-level isolated material; time-consuming
GC-MS/Headspace GC	Volatile degradants, residual solvents	Ideal for volatiles; fast	Not suitable for non-volatile or thermolabile compounds
UHPLC	High-throughput stability-indicating assay	Short run time; high efficiency; low solvent use	Column equivalency; system pressure requirements

RP-HPLC = reversed-phase high-performance liquid chromatography; PDA = photodiode array; ELSD = evaporative light-scattering detector; CAD = charged aerosol detector; ESI = electrospray ionisation; Q-TOF = quadrupole time-of-flight; HRMS = high-resolution mass spectrometry; UHPLC = ultra-high-performance liquid chromatography; NMR = nuclear magnetic resonance; GC-MS = gas chromatography mass spectrometry; LC-MS = liquid chromatography mass spectrometry.

4.6. Peak Purity and Co-Elution Assessment

Peak purity may be assessed using the three-dimensional (3D) spectral plot function in Empower™ chromatography data software (Waters Corporation, Milford, MA, USA) or similar platforms (e.g., Openlab, Chromeleon, LabSolutions) to confirm the absence of co-eluting impurities at the retention times of the drug substance and all specified degradants. It is assessed by PDA and is defined as the absence of spectral contributions from co-eluting species with different UV absorption characteristics at a given chromatographic peak. In Empower, peak purity assessment typically compares spectra acquired across the chromatographic peak profile, with a purity angle less than the purity threshold indicating spectral homogeneity. The peak purity must be assessed both for drug substance and known impurities peaks. It must be recognized that peak purity analysis is limited to co-eluters with distinguishably different UV spectra; for co-eluters with identical chromophores, orthogonal techniques such as MS, 2D-HPLC may provide additional confirmation.

4.7. Mass Balance Evaluation

Mass balance, defined as the sum of the drug substance assay value and all quantifiable degradation products expressed as a percentage of the unstressed reference, is a critical criterion for demonstrating the stability-indicating character of an analytical method. A typical mass balance range of 95% - 105% is widely accepted. The deviations from this range should be investigated: common causes include chromophore-free degradants undetectable by UV (remediated by ELSD/CAD detection); volatile degradants lost during sample preparation (remediated by headspace GC); formation of insoluble species that precipitate from solution; co-elution of unresolved degradants under a main peak (remediated by gradient optimization); degradants eluting late (remediated by extending run time and followed

by introduction of gradient optimization); significant differences in molar absorptivity between parent and degradant at the detection wavelength (remediated by response factor correction or reference standard-based quantitation); Formation of degradants with absorbance maxima at wavelengths different from primary detection wavelength (remediated by measuring those degradants at their respective λ~max wavelengths and combining the results with those of the impurities measured at the primary detection wavelength) [30] [31]. In some cases, the calculated mass balance may exceed 105% due to differences in detector response between the active pharmaceutical ingredient (API) and unknown degradants. Specifically, if an unknown degradant has a relative response factor (RRF) greater than 1 but is quantified assuming an RRF of 1, the calculated impurity level may be overestimated, resulting in a mass balance greater than 105%. The forced degradation workflow for stability assessment is presented in **Figure 5**. The mass balance and percentage degradation should be verified using the following equations.

$$\text{Mass Balance} = \frac{\%\text{Assay of Stressed Active} + \%\text{Known Degradation Products} + \%\text{Unknown Degradation Products}}{\%\text{Assay of Unstressed Active}}$$

$$\%\text{Degradation} = 100 - \left[\frac{\text{Stressed sample main peak area}}{\text{Control sample main peak area}} \times \frac{\text{Control Spl.Wt}}{\text{Stressed Spl.Wt}} \times 100\right]. \quad (2)$$



Figure 5. Forced degradation workflow for stability assessment.

5. Method Development Design Strategy

5.1. Analytical Target Profile

In alignment with ICH Q14, method development may begin with the definition of an Analytical Target Profile (ATP): a prospective specification of the performance characteristics required of the method to fulfil its intended purpose. The ATP for a stability-indicating assay of a solid oral drug substance and drug product would typically specify: 1) analyte identity (DS and specified degradants/impurities); 2) measurement range (typically 50% - 150% of nominal test concentration for assay; LOQ to 150% of reporting threshold for impurities); 3) required precision; 4) required accuracy; 5) specificity; and 6) LOQ at or below the applicable ICH Q3B(R2) reporting threshold. Systematic method development using Design of Experiments (DoE), typically involving a screening design (e.g., Plack-

ett-Burman or fractional factorial) followed by a response surface methodology (RSM) (Box-Behnken or Central Composite), enables simultaneous evaluation of multiple chromatographic variables and identification of both significant main effects and interaction effects. Variables typically screened include pH of aqueous mobile phase component, organic modifier type and concentration gradient profile, column stationary phase chemistry, column temperature, and flow rate. The MODR, the set of conditions within which all ATP requirements are simultaneously met, is then established from the DoE model. The steps for validating the stability-indicating method are presented in Figure 6.

Figure 6. Steps for validating a stability-indicating method.

5.2. Chromatographic Platform Selection

Reversed-phase HPLC on C18 (USP L1) or C8 (USP L7) stationary phases is the predominant platform for stability-indicating method development in pharma-

ceutical drug substance and drug products, owing to its broad applicability to molecules of log P between −2 and +5, compatibility with aqueous matrices, well-understood selectivity parameters, and universal regulatory acceptance. UHPLC on sub-2-μm particles provides significantly higher efficiency (theoretical plates N > 20,000) and shorter run times compared with conventional 5-μm HPLC, with equivalent or superior resolution; it is increasingly adopted for stability-indicating methods where throughput is critical. For basic compounds susceptible to peak tailing on silica-based C18 columns, options include use of hybrid silica particles (BEH, HSS technology) with improved pH stability and reduced silanol activity; addition of ion-pairing agents (trifluoroacetic acid, heptafluorobutyric acid) to suppress silanol interactions; or application of mixed-mode stationary phases (C18/ion exchange). For acidic drugs, low-pH mobile phases (pH 2.0 - 3.0) typically suppress ionization and improve peak shape. Mobile phase pH should be carefully controlled (typically ± 0.05 units) using appropriate buffer systems such as phosphate, acetate, formate, and ammonium bicarbonate.

5.3. General Recommended Chromatographic Conditions for Drug Substance and Drug Product Stability-Indicating Methods

Based on current best practice and literature survey, the following represent broadly applicable starting conditions for RP-HPLC stability-indicating methods for many small-molecule drug substances and drug products:

- Stationary Phase: C18 column (150 - 250 mm × 4.6 mm, 3.5 - 5 μm) or UHPLC equivalent (50 - 150 mm × 2.1 mm, 1.7 - 1.8 μm); USP L1 specification; end-capped, low-bleed.
- Mobile Phase A: Non-volatile buffers (phosphate, sodium, and potassium salts); 10 - 50 mM volatile buffer (ammonium formate pH 3.0 - 4.5; ammonium acetate pH 4.5 - 6.0; or 0.1% formic acid in water for MS compatibility).
- Mobile Phase B: Acetonitrile or methanol (acetonitrile preferred for lower UV cut-off and lower viscosity).
- Gradient Profile: Begin at 5% - 20% B; ramp to 80% - 95% B over 20 - 30 min (analytical) or 8 - 12 min (UHPLC); hold 3 - 5 min; re-equilibrate 5 - 10 min.
- Flow Rate: 0.8 - 1.5 mL/min (analytical); 0.3 - 0.5 mL/min (UHPLC).
- Column Temperature: 30˚C - 40˚C (controlled ± 1˚C); documented as critical if robustness-significant.
- Detection Wavelength: Primary UV absorption maximum of the DS; PDA acquisition 200 - 400 nm.
- Injection Volume: 5 - 20 μL; matched to column geometry and sample concentration.
- Diluent: Matched to initial mobile phase composition, or miscible solvent (e.g., methanol: water 50:50 v/v)
- System Suitability: Typically includes tailing factor between 0.8 to 1.8; USP Plate Count N ≥ 2000 plates; USP Resolution Rs ≥ 2.0 (DS vs. nearest degradant); %RSD ≤ 2.0% (n = 5, peak area).

For MS-coupled methods (LC-MS/MS or LC-HRMS), non-volatile buffers (phosphate, sodium, potassium salts) must be replaced with volatile equivalents (ammonium formate, ammonium acetate, formic acid, acetic acid) to prevent source contamination. Trifluoroacetic acid concentration should be limited to ≤0.05% to avoid ion suppression in positive ESI mode.

5.4. Sample Preparation for Drug Substance and Drug Products

Representative sample preparation involves: 1) accurately weighing the sample into a volumetric flask to obtain the nominal concentration; 2) adding approximately 75% of the final volume of diluent, followed by hand vortexing, sonication, and/or mechanical shaking as appropriate to dissolve the sample; 3) diluting to volume with diluent; 4) centrifugation and/or membrane filtration using a 0.2 or 0.45 μm syringe filter (e.g., PTFE, Nylon, PVDF); and 5) discarding the first 1 - 3 mL of filtrate to saturate the membrane.

6. Validation of Stability-Indicating Analytical Methods: Principles and Current Practices

6.1. Validation Strategy and Documentation

Method validation must be performed prior to using the method for its intended purpose (batch release, stability testing, comparability studies, etc.) and in accordance with applicable regulatory expectations. A formal validation protocol, approved before experimentation, defines the validation scope, analytical procedure version, reference standards to be used, acceptance criteria for each validation characteristic, and the number of determinations at each experimental level. Results are documented in a Validation Report that includes data, statistical analyses, representative chromatograms, and an explicit pass/fail conclusion against each acceptance criterion. The validation scope for a new stability-indicating RP-HPLC method for a drug product must address both the assay of the drug substance and the related substances (degradants/impurities) determination. Where the same chromatographic method serves both purposes, the validation covers both test procedures. Compendial methods adopted without modification require only system suitability demonstration and, where indicated by USP <1225>, and USP <1226>, rather than full revalidation [32]-[49].

6.2. Validation Parameters and Acceptance Criteria

According to the United States Pharmacopeia (USP), analytical procedures are classified into four categories based on their intended purpose. Category I comprises analytical procedures used for the quantitative determination of major components in bulk drug substances or active pharmaceutical ingredients (APIs), including preservatives, in finished pharmaceutical products. Category II includes analytical procedures for the determination of impurities in bulk drug substances and degradation products in finished pharmaceutical products, encompassing both quantitative assays and limit tests. Category III consists of analytical procedures

designed to evaluate performance characteristics, such as dissolution and drug release. Category IV includes analytical procedures used for the identification of drug substances and pharmaceutical products. Listed in Table 4 are data elements that are normally required for each of these categories. The validation parameters are presented in Figure 7.

Table 4. Data elements required for validation.

Characteristics	Category I	Category II (Quantitative)	Category II (Limit Tests)	Category III	Category IV
Accuracy	Yes	Yes	*	*	No
Precision	Yes	Yes	No	Yes	No
Specificity	Yes	Yes	Yes	*	Yes
Detection Limit	No	No	Yes	*	No
Quantitation Limit	No	Yes	No	*	No
Linearity	Yes	Yes	No	*	No
Range	Yes	Yes	*	*	No

*May be required, depending on the nature of the specific test.



Figure 7. Analytical method validation parameters.

Table 5 presents a comprehensive summary of all ICH Q2(R2) validation parameters, their applicability to assay and related substances categories, acceptance criteria, and recommended experimental design for a stability-indicating drug product method. Note that the acceptance criteria presented in the table are based on the authors' experience with drug product analytical methods. For drug substances, tighter acceptance criteria are generally expected, and filter compatibility studies are typically not applicable. During the validation, spiking for drug substances is typically performed in the diluent, whereas for drug products, spiking is performed in the placebo to account for potential interactions with excipients. The acceptance criteria provided should be considered as general guidance, and wider acceptance limits may be acceptable when scientifically justified based on product specifications and analytical method performance.

Based on forced degradation studies, impurities are classified as process-related impurities and degradants. Process-related impurities are controlled during the drug substance manufacturing stage and, therefore, are excluded from the calculation of total impurities. Linearity and accuracy will be established for both the drug substance and the degradants. In addition, the relative response factors (RRFs) of the degradants will be determined as part of the method validation study.

Table 5. Comprehensive summary of ICH Q2(R2) validation parameters, acceptance criteria, and experimental design for a stability-indicating RP-HPLC drug product method.

Parameter	Test	Acceptance Criteria	Key Experimental Design
System Suitability	Assay & RS	%RSD NMT 2.0%; USP tailing factor between 0.8 and 1.8; USP plate count NLT 2000. USP Resolution must be >2.0 (co-eluting peaks).	Five replicate injections at the 100% standard level
Specificity	Assay & RS	No excipient interference; Rs ≥ 2.0 between the main peak and all degradants; PDA peak purity angle < purity threshold.	Placebo spike; co-injection with all available RS; analysis of all FD-stressed samples
Linearity	Assay	Coefficient of correlation r ≥ 0.999; y-intercept ≤ 2.0% at the 100% level response; y-difference ≤ 2.0%.	≥5 levels, 50% - 150% nominal concentration; independent preparations from fresh weighing
Linearity	RS	r ≥ 0.98; y-intercept ≤ 20.0% at the 1% level response; y-difference ≤ 20.0%.	≥5 levels from LOQ to 150% of specification limit
Full Level Linearity	Assay & RS	r ≥ 0.995; y-intercept ≤ 2.0% at the 100% level response	Combination of assay and related substances linearity
Accuracy	Assay	97.0% - 103.0% recovery at 50%, 100%, and 150% levels for each level (n = 3) and overall (n = 9); %RSD NMT 3.0% at each level and overall	Standard addition to placebo matrix; n = 3 per level; ≥9 total determinations
Accuracy	RS	75.0% - 125.0% recovery at LOQ-150% specification limit; %RSD NMT 25.0% at each level and overall	Spike known impurity/degradant reference standards at 3 levels; n = 3 each
Precision (Analyst 1)	Assay & RS	%RSD ≤ 3.0% (n = 6, same day/analyst)	Six independent sample preparations analyzed
Intermediate Precision (Analyst 2)	Assay & RS	%RSD ≤ 3.0% (n = 6); absolute difference in %LC between Analyst 1 and Analyst 2 NMT 3.0%; relative difference in %impurity between Analyst 1 and Analyst 2 NMT 30.0%	Six independent sample preparations analyzed sequentially using different days, analysts, and instruments
Range	Assay & RS	For assay coefficient of correlation r ≥ 0.99. For related substance coefficient of correlation r ≥ 0.98.	Defined by linearity and accuracy data

Continued

Filter	Assay & RS	No adsorption or extraction observed; %LC in filtered sample solutions within ±2.0% (absolute difference) of centrifuged sample solutions; relative difference in %impurity between centrifuged and each filtrate condition NMT 30.0%.	Comparison of filtrate versus centrifuged sample
LOD	RS	S/N ≥ 3; confirmed by injection	Serial dilution; visual confirmation at proposed LOD
LOQ	RS	S/N ≥ 10; %RSD ≤ 20.0%; ≤reporting threshold	Six replicate injections at LOQ level; confirm accuracy and precision
Robustness	Assay & RS	System suitability criteria met; %RSD ≤ 2.0% under all variations; change within ±2.0% of robustness and nominal assay value; relative difference in %impurity between nominal and each robustness condition NMT 30.0%.	Plackett-Burman design (7 variables, 8 experiments); main effects analysis
Standard Stability	Assay & RS	Standard agreement must be 98.0% - 102.0% of the initial standard area	Analysis at 0, 48, and 72 h under benchtop (RT) and refrigerated (2˚C - 8˚C) conditions
Sample Stability	Assay & RS	Change within ±2.0% of the initial assay value; relative difference in %impurity between nominal and each stability condition NMT 30.0%	Analysis at 0, 48, and 72 h under benchtop (RT) and refrigerated (2˚C - 8˚C) conditions

6.2.1. System Suitability

System suitability testing will be performed prior to the evaluation of each validation parameter to demonstrate the adequacy of the chromatographic system. The system suitability assessment will include the injection of five replicate standard preparations, and the percent relative standard deviation (%RSD) of the peak responses will be calculated. In addition, chromatographic performance will be evaluated by determining the USP tailing factor, USP theoretical plate count, and USP resolution for all critical pairs, including co-eluting peaks. All system suitability results will be assessed against the predefined acceptance criteria specified in protocol before proceeding with sample analysis.

$$\%\text{RSD} = \frac{\text{Standard Deviation}}{\text{Average Peak Area}\left(n=5\right)} \times 100\,. \tag{3}$$

6.2.2. Specificity

Specificity is ability to assess unequivocally the analyte in the presence of components that may be expected to be present, such as impurities, degradation products, and matrix components. Specificity is the foundational validation characteristic for a stability-indicating method, as it establishes that the method measures the intended analyte without positive interference from other components. It is demonstrated through four complementary experiments: 1) placebo challenge anal-

ysis of the drug product placebo at the test concentration confirms no excipient peak interferes with the DS peak or known degradant peaks; 2) forced degradation specificity analysis of all stressed samples (from all six or more stress conditions) demonstrates that degradant peaks are resolved from the main peak (Rs ≥ 2.0) and from each other; 3) peak purity by PDA confirms spectral homogeneity of the DS and major degradant peaks across all stressed chromatograms; and 4) co-injection specificity test solution spiked with all available impurity and degradant reference standards confirms individual peak assignments. When an authentic reference standard is not available for a degradant observed above the identification threshold, the forced degradation sample containing that degradant serves as a specificity surrogate, with the caveat that the relative retention time (RRT) of the degradant peak is documented as the identity reference until a reference standard becomes available. This approach is consistent with the principles described in ICH Q2(R2) and USP <1225>.

6.2.3. Linearity

The linearity of an analytical method is its ability to elicit test results that are directly, or by a well-defined mathematical transformation, proportional to the concentration of analyte in samples within a given range. Linearity is typically assessed at a minimum of five concentration levels, each prepared independently from fresh weighing of the reference standard to propagate independent weighing errors. For the assay method, the range is 50% - 150% of the nominal test concentration; for the related substances method, the range is from the LOQ to at least 150% of the applicable specification limit or reporting threshold for both DS and known degradant. Additionally, a full level linearity may be evaluated by combining assay and related substance linearity levels to understand the bias of using a single level standard for system suitability. The assay and related substance linearity model is evaluated by the coefficient of correlation r, %y-intercept and % y-difference. Relative Response Factor (RRF) for Degradants is determined using the slope of DS and known impurity at related substance level.

$$y = mx + b \tag{4}$$

where y = peak area, x = concentration, m = slope, b = y-intercept.

$$\text{Y bias} = \frac{\text{Y-intercept}}{\text{Peak Area at 100\% or 1\%}} * 100\,. \tag{5}$$

100% peak area for assay level and 1% peak area for Related Substance level

$$\%\text{Y Difference} = \frac{\left|C_{\text{eq}} - C_{\text{weights}}\right|}{C_{\text{weights}}} * 100 \tag{6}$$

where C_{eq} = Actual concentration from Linearity curve equation. C_{weights} = Theoretical concentration from weights

$$\text{RRF} = \frac{\text{Slope of Impurity}}{\text{Slope of Main peak}}\,. \tag{7}$$

6.2.4. Accuracy

The accuracy of an analytical method is the closeness of test results obtained by that method to the true value. The accuracy of an analytical method should be established across its range. Accuracy for the drug product assay is evaluated by the standard addition method, adding the DS reference standard to the drug product placebo matrix at three concentration levels (50%, 100%, and 150%) with three replicates per level. For the related substances method, accuracy is assessed for each specified degradant/impurity at three levels (LOQ, nominal specification limit, 150% specification limit) using its respective reference standard or estimated via response factor where the standard is unavailable. The % recovery is calculated using amount found and amount added. The accuracy model is evaluated using the percentage recovery and %RSD at each level ($n = 3$) and across all levels ($n = 9$ total determinations). The accuracy control is prepared in the diluent and placebo to see the different effects of extraction procedure.

$$\%\text{Recovery} = \frac{\text{Amount Found}}{\text{Amound Added}} * 100 . \quad (8)$$

6.2.5. Method Precision

The precision of an analytical method is defined as the degree of agreement among individual test results when the method is applied repeatedly to multiple samplings of a homogeneous sample. Repeatability (intra-assay precision) is assessed using six independent sample preparations analyzed by a single analyst on one instrument within one day ($n = 6$). The spiked precision is performed when the drug product or drug substance does not contain impurities above the limit of quantification (LOQ), for comparison purposes. In such cases, impurities are spiked at the specification level. A similar spiked sample preparation is used for evaluation of method ruggedness, filter study, and sample solution stability.

$$\%\text{RSD} = \frac{\text{Standard Deviation}}{\text{Average \%Assay or Label Claim}\left(n = 6\right)} \times 100 . \quad (9)$$

6.2.6. Ruggedness

The ruggedness (intermediate Precision) of an analytical method is the degree of reproducibility of test results obtained by the analysis of the same samples under a variety of conditions, such as different laboratories, analysts, instruments, and days.

$$\%\text{Abosolute Difference} = \text{Method Precision} - \text{Intermediate Precision} . \quad (10)$$

Note: Alternate calculations such as %RSD. % Difference, ANOVA and Confidence Intervals may also be employed to compare with the method precision data.

6.2.7. Range

The range of an analytical method is the interval between the upper and lower levels of analyte (including these levels) that has been demonstrated to be determined with an acceptable level of precision, accuracy, and linearity using the method. The range is evaluated using the correlation coefficient (r) obtained from the re-

lationship between the amount added and the analytical response generated from the accuracy data. The assay range is typically 50% - 150% of the nominal concentration, whereas the related substances range extends from the LOQ to 150% of the specification limit.

6.2.8. Filter Study

Diluent, spiked sample, and placebo preparations are filtered using a 0.45 µm PTFE + GF syringe filter and compared with the corresponding unfiltered aliquots to assess potential filter-related effects. For unfiltered preparations, sample solutions are typically centrifuged at 4000 RPM for 15 minutes prior to injection. The centrifugation time may be extended, when necessary, to minimize matrix-related interference in the chromatographic system. During filtration assessment, sequential portions of the initial 1 mL, 2 mL, 3 mL, and 4 mL filtrates are discarded, and subsequent filtrate portions are collected for analysis. Filtered and centrifuged (unfiltered) samples are evaluated for potential filter-derived interferences, analyte adsorption, or recovery bias. The assay of the active substance, known degradation products, and unknown impurities is determined for each preparation, and the absolute differences between filtered and unfiltered results are calculated for individual analytes. This approach supports the evaluation of filter compatibility and ensures that the selected filtration procedure does not adversely impact analytical performance.

6.2.9. Limits of Detection and Quantitation

LOD is a characteristic of limit tests. It is the lowest amount of analyte in a sample that can be detected, but not necessarily quantitated, under the stated experimental conditions. The LOQ is the lowest amount of analyte in a sample that can be determined with acceptable precision and accuracy under the stated experimental conditions. LOD and LOQ are determined by the signal-to-noise (S/N) ratio method: serial dilutions of the reference standard (or surrogate FD sample) are injected, and the S/N ratio is computed for each concentration. LOD is defined as the concentration giving S/N ≥ 3 (confirmed by three replicate injections showing detectable signal above baseline noise); LOQ is the concentration giving S/N ≥ 10 with %RSD ≤ 20.0% from six replicate injections. The LOQ must be at or below the applicable ICH Q3B(R2) reporting threshold to ensure all regulatorily reportable degradants are quantifiable.

$$\mathrm{LOQ} = \frac{10\sigma}{S} \quad \text{and} \quad \mathrm{LOD} = \frac{3.3\sigma}{S} \tag{11}$$

where σ = the standard deviation of the response S = the slope of the calibration curve.

6.2.10. Robustness

The robustness of an analytical method is a measure of its capacity to remain unaffected by small but deliberate variations in method parameters and provides an indication of its reliability during normal usage. A Plackett-Burman design (res-

olution III fractional factorial) evaluating seven factors in eight experiments is one commonly used screening design for robustness. Typical factors for RP-HPLC methods include mobile phase pH (±0.2 units); organic modifier content (±2% - 5%); flow rate (±0.1 mL/min); column temperature (±5˚C); detection wavelength (±2 nm); injection volume (±2 µL); and column lot/manufacturer. Main effects analysis identifies factors that significantly affect system suitability criteria (peak area %RSD, Rs, tailing factor) at the test range; such factors are designated critical method parameters and must be controlled within tighter limits in the final method procedure. Where a Q14/QbD approach is employed, the MODR may be defined as the region of method parameter space in which all system suitability and acceptance criteria are simultaneously met. Diluent, standard, spiked sample, and placebo preparations are injected during the robustness study.

$$\%\text{Difference for Sample} = \frac{\text{Absolute}\left(\text{Initial Result} - \text{Each Robustness Result}\right)}{\text{Initial Result}} * 100. \quad (12)$$

6.2.11. Solution Stability

Solution stability demonstrates that the standard and sample solutions remain analytically equivalent over the period required for routine laboratory analysis. Stability is assessed at room temperature (bench-top, protected from light) and under refrigerated storage (2˚C - 8˚C), at 0, 48, and 72 h. The stability will be determined against a freshly prepared working standard at each time point. Solution stability data directly defines the maximum permissible time between sample preparation and injection and between preparation of the reference standard and its last use in an analytical sequence.

$$\%\text{Difference for Standard} = \frac{\text{Absolute}\left(\text{Initial Peak Area} - \text{Stability Point Peak Area}\right)}{\text{Initial Peak Area}} * 100. \quad (13)$$

$$\%\text{Difference for Sample} = \frac{\text{Absolute}\left(\text{Initial Result} - \text{Stability Point Result}\right)}{\text{Initial Result}} * 100. \quad (14)$$

7. Discussion

7.1. Integration of Forced Degradation and Method Validation: An Iterative Workflow

Forced degradation studies and analytical method validation are scientifically interdependent activities that are often conducted within an integrated, iterative workflow rather than as sequential discrete studies. Preliminary forced degradation experiments using initial, non-optimized chromatographic conditions identify the number, approximate polarity, and UV characteristics of primary degradants, which in turn inform the gradient elution program and detection wavelength selection during method development. Once the chromatographic method is developed and degradants are resolved, a second, confirmatory round of forced

degradation samples prepared at the optimized conditions provides the definitive specificity data for validation. Only after this confirmatory specificity demonstration should full ICH Q2(R2) validation be initiated. A common deficiency in both academic publications and regulatory submissions is the inadequate treatment of mass balance failures. When mass balance deviates significantly from the expected value, typically approaching 100%, the scientific investigation should be systematic and exhaustive: UV-transparent degradants may be investigated using orthogonal detectors such as ELSD or CAD; volatile species by headspace GC; precipitate formation by visual inspection and recovery from the solid; and co-elution under the main peak by 2D-HPLC or high-resolution MS. In submissions, unexplained mass balance deficits are a frequent target of regulatory queries and are remediable at the development stage if systematically investigated.

7.2. Degradant Identification: From Detection to Structure Elucidation

A tiered, threshold-driven identification strategy is most efficient and cost-effective. Below the ICH Q3B(R2) reporting threshold, degradants are often monitored and tracked using relative retention time (RRT) without the need for extensive structural identification. Between the reporting and identification thresholds, additional characterization may be warranted, commonly using techniques such as LC-MS/MS (to provide a molecular ion and fragmentation pattern). At or above the identification threshold, definitive structure elucidation by LC-HRMS (exact mass, molecular formula) and NMR (^{1}H, ^{13}C, and 2D correlation experiments) may be required for the regulatory submissions. At or above the qualification threshold, additional toxicological justification, qualification, or safety assessment may be required in accordance with ICH Q3B(R2). Advances in data-independent acquisition (DIA) mass spectrometry and *in silico* degradation prediction software (e.g., Zeneth®, MDL-ISIS) are beginning to augment though not yet replace experimental forced degradation and structure elucidation. These tools enable prospective prediction of the most likely degradation products based on known chemical reactivity rules, guiding experimental forced degradation protocols and enabling more targeted LC-MS/MS experiments [50]-[57]. However, the regulatory community has not yet established clear guidance on the acceptable use of *in silico* data as a substitute for experimental structural elucidation. The tiered analytical strategy for unknown degradation product identification is presented in **Figure 8**.

7.3. Critical Evaluation of Published Forced Degradation Literature

A critical survey of published forced degradation literature reveals several deficiencies that limit the utility of such studies as regulatory-grade evidence. First, many publications apply only acid, base, and oxidative stress, omitting photolytic, thermal, and humid/thermal conditions, providing an incomplete stability profile.



Figure 8. Tiered analytical strategy for unknown degradation product identification.

Second, most published methods use isocratic or poorly optimized gradient elution, resulting in poor resolution of closely eluting degradants and raising the possibility that co-eluting peaks inflate the apparent assay value or are missed entirely. Third, mass balance calculations are frequently absent or incomplete, limiting confidence in the stability-indicating claim. Fourth, degradant identification based solely on UV spectral comparison may be insufficient for degradation products requiring structural characterization, for which orthogonal techniques such as MS confirmation are often expected by regulatory reviewers. Future publications in this field would benefit from adopting the reporting standards implicit in current regulatory guidance: documentation of the complete set of stress conditions (in-

cluding negative findings with justification); time-course degradation profiles; complete mass balance data with investigation of any deviations; MS or HRMS data for degradants above the identification threshold; and a full ICH Q2(R2) validation dataset rather than abbreviated characterization studies.

7.4. Regulatory Convergence and Jurisdiction-Specific Requirements

The ICH harmonization process has substantially reduced regulatory divergence among the major markets (U.S., EU, Japan, Canada, Australia, and Switzerland). However, significant differences persist at the level of regional regulatory authority guidance. ANVISA RDC 53/2015 is uniquely prescriptive in requiring a minimum 10% degradation, mandating metal-ion stress as a separate condition, and requiring repetition of the forced degradation program for each change of API manufacturer. The PMDA (Japan) requires cross-validation against pharmacopoeia compendial methods where the product is described in the JP. Emerging markets (ASEAN, Gulf Cooperation Council, African Union) increasingly adopt WHO or ICH guidelines as their primary reference but with country-specific variations that must be individually verified. For global regulatory submissions, a pragmatic approach is often to design the forced degradation studies to satisfy the most stringent applicable regulatory requirements (currently ANVISA), thereby ensuring that the resulting dataset will satisfy support submissions across multiple regulatory markets. This strategy avoids the need for jurisdiction-specific supplementary studies and reduces total development cost and timeline [58]-[64].

7.5. Lifecycle Management of Analytical Procedures: ICH Q14 and the Future

The ICH Q14 guideline (Step 4, November 2023) and the associated revision of ICH Q2 to Q2(R2) represent a significant evolution in analytical development and validation philosophy since the original Q2 guideline in 1994. The key elements of the Q14 framework, Analytical Target Profile, DoE-based development, MODR definition, and analytical procedure control strategy transform validation from a one-time compliance activity to a continuous performance monitoring program integrated into the pharmaceutical quality system. Under ICH Q14, a regulatory submission incorporating a defined MODR may qualify for a reduced-reporting or notification-only change management path for post-approval analytical changes, a significant regulatory benefit that reduces submission burden and approval timelines. The major regulatory agencies (FDA, EMA) have issued parallel guidance or concept papers endorsing this approach, and it is progressively being adopted in new submissions by innovator pharmaceutical companies [65]-[68]. Generic manufacturers are increasingly exploring adoption of these principles, and the expectation is that Q14-aligned submissions will become the standard within the current regulatory cycle.

7.6. Emerging Technologies and Future Directions

Several emerging analytical technologies are poised to significantly enhance the practice of forced degradation and stability-indicating method development in coming years:

- **Two-Dimensional Liquid Chromatography (2D-LC):** Orthogonal separation in two dimensions provides dramatically enhanced peak capacity (>1000 for comprehensive 2D-LC), enabling resolution of degradant pairs that co-elute in conventional 1D-HPLC. Particularly valuable for complex fixed-dose combination drug products with multiple APIs and overlapping degradant profiles.
- **Charged Aerosol Detector (CAD) and ELSD:** These universal detectors, increasingly used alongside PDA, provide equimolar (near-equimolar for CAD) response independent of UV chromophore, supporting detection of UV-transparent degradants and potentially improving mass balance assessments with or without requirement for reference standards.
- **Ion Mobility-Mass Spectrometry (IM-MS):** Separation by molecular shape (collision cross-section) orthogonal to m/z provides an additional dimension of selectivity for structural isomer discrimination, particularly valuable for stereoisomeric degradants where conventional MS and NMR yield ambiguous assignments [69].
- ***In Silico* Degradation Prediction:** Machine-learning-based models trained on large pharmaceutical degradation databases (e.g., Zeneth®, Lhasa Limited) can assist in predicting the most likely degradation products from molecular structure, enabling more targeted and efficient experimental forced degradation design [70].
- **Real-Time Release Testing (RTRT) and Process Analytical Technology (PAT):** ICH Q8(R2) and related FDA guidance encourage the replacement of end-product analytical testing with real-time process monitoring using inline/online sensors (NIR, Raman, UV-Vis probes), which has the potential to significantly influence batch-based quality assurance for continuous manufacturing platforms.

8. Conclusion

This overview presents a comprehensive and critically evaluated framework for forced degradation studies and analytical method validation as applied to pharmaceutical drug substances and drug products. The principal conclusions are as follows: Forced degradation studies, commonly designed to achieve 5% - 20% degradation of the parent compound under a range of relevant stress conditions, are both a regulatory requirement and a scientific necessity for pharmaceutical drug product development. Where appropriate, the study scope should encompass both the drug substance and the drug product matrix, including placebo controls, to provide a complete degradation profile relevant to shelf-life stability. The principal degradation pathways, hydrolytic, oxidative, photolytic, thermolytic, and ex-

cipient interaction-mediated, should be mechanistically understood to guide both the experimental design of forced degradation studies and the structural interpretation of degradant data. A tiered analytical approach consisting of HPLC/UHPLC with PDA for routine detection, peak purity assessment, and quantitation; LC-MS/MS for identity confirmation above the reporting threshold; and LC-HRMS/NMR for definitive structure elucidation above the identification and qualification thresholds represents current best practice aligned with ICH Q3B(R2) requirements. Mass balance (often approximately 95% - 105%) is a critical indicator for confirming the stability-indicating nature of the method. Any deviations should be systematically investigated using orthogonal detection techniques such as ELSD/CAD, headspace GC, and MS, and should be documented with appropriate scientific justification in regulatory submissions. This overview is intended to serve as a broadly applicable reference framework. Future work should focus on the integration of *in silico* degradation prediction with experimental forced degradation study design, the adoption of universal detection methods for complete mass balance accountability, and the development of internationally harmonized standards for reporting forced degradation data in regulatory submissions to reduce the current fragmentation of global requirements.

Author Contributions

S.K.B. conceptualized the study, developed the overall framework and manuscript structure, conducted a comprehensive literature review, interpreted the regulatory and analytical data, prepared all figures and tables, integrated the scientific content, and wrote the original manuscript draft. R.T.M. contributed to the study design, assisted with the literature review, interpreted the data, and critically reviewed and revised the manuscript. M.C.B. assisted with the literature review and contributed to manuscript review and editing. R.B.S. and A.M. critically reviewed and edited the manuscript and provided input on analytical method validation principles and regulatory requirements.

All authors reviewed, edited, and approved the final manuscript and agreed to be accountable for all aspects of the work.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] Zelesky, T., Baertschi, S.W., Foti, C., Allain, L.R., Hostyn, S., Franca, J.R., *et al.* (2023) Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective. *Journal of Pharmaceutical Sciences*, **112**, 2948-2964. https://doi.org/10.1016/j.xphs.2023.09.003

[2] Campbell, J.M., Colombo, S., Doyle, J.L., Filoti, D.I., Hübner, G., Magnenat, L., *et al.* (2024) An Industry Perspective on the Use of Forced Degradation Studies to Assess Comparability of Biopharmaceuticals. *Journal of Pharmaceutical Sciences*, **113**, 505-512. https://doi.org/10.1016/j.xphs.2023.12.011

[3] Marden, S., Campbell, J.M., Adams, N., Coelho, R., Foti, C., Franca, J.R., *et al.* (2024) Mass Balance in Pharmaceutical Stress Testing: A Review of Principles and Practical Applications. *The AAPS Journal*, **26**, Article No. 96. https://doi.org/10.1208/s12248-024-00961-3

[4] Campbell, J.M., Foti, C., Wang, C., Adams, N., Allain, L.R., Araujo, G., *et al.* (2022) Assessing the Relevance of Solution Phase Stress Testing of Solid Dosage Form Drug Products: A Cross-Industry Benchmarking Study. *Journal of Pharmaceutical Sciences*, **111**, 298-305. https://doi.org/10.1016/j.xphs.2021.06.012

[5] Bhangare, D., Rajput, N., Jadav, T., Sahu, A.K., Tekade, R.K. and Sengupta, P. (2022) Systematic Strategies for Degradation Kinetic Study of Pharmaceuticals: An Issue of Utmost Importance Concerning Current Stability Analysis Practices. *Journal of Analytical Science and Technology*, **13**, Article No. 17. https://doi.org/10.1186/s40543-022-00317-6

[6] Singh, S., Junwal, M., Modhe, G., Tiwari, H., Kurmi, M., Parashar, N., *et al.* (2013) Forced Degradation Studies to Assess the Stability of Drugs and Products. *TrAC Trends in Analytical Chemistry*, **49**, 71-88. https://doi.org/10.1016/j.trac.2013.05.006

[7] ICH Harmonised Guideline Q1A(R2) (2003) Stability Testing of New Drug Substances and Products. International Council for Harmonisation Secretariat. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf

[8] ICH Harmonised Guideline Q1B (1998) Photostability Testing of New Drug Substances and Products. International Council for Harmonisation Secretariat. https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf

[9] ICH Harmonised Guideline Q2(R2) (2023) Validation of Analytical Procedures. International Council for Harmonisation Secretariat. https://database.ich.org/sites/default/files/ICH_Q2(R2)_Guideline_2023_1130.pdf

[10] ICH Harmonised Guideline Q14 (2023) Analytical Procedure Development. International Council for Harmonisation Secretariat. https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116.pdf

[11] Ettaboina, S.K., Nannapaneni, S., Katari, N.K. and Chollety, V.K. (2025) Development and Validation of an RP-HPLC Method for Organic Impurity Profiling in Baclofen Utilizing Robustness through a Quality-by-Design (QbD) Approach: A Comprehensive Forced Degradation Assessment. *Biomedical Chromatography*, **39**, e70129. https://doi.org/10.1002/bmc.70129

[12] Godani, N., Mudaliar, S., Pai, R. and Sharma, S. (2024) Leveraging Principles of QbD for Analytical Method Development and Validation for the Estimation of Eltrombopag Olamine in Tablet Dosage Forms by HPLC. *Chromatographia*, **87**, 635-648. https://doi.org/10.1007/s10337-024-04356-6

[13] Sha'at, M., Spac, A.F., Stoleriu, I., Bujor, A., Cretan, M.S., Hartan, M., *et al.* (2022) Implementation of QbD Approach to the Analytical Method Development and Validation for the Estimation of Metformin Hydrochloride in Tablet Dosage Forms by HPLC. *Pharmaceutics*, **14**, Article No. 1187. https://doi.org/10.3390/pharmaceutics14061187

[14] ICH Harmonised Guideline Q3A(R2) (2006) Impurities in New Drug Substances. International Council for Harmonisation Secretariat. https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf

[15] ICH Harmonised Guideline Q3B(R2) (2006) Impurities in New Drug Products. International Council for Harmonisation Secretariat. https://database.ich.org/sites/default/files/Q3B%28R2%29%20Guideline.pdf

[16] ICH Harmonised Guideline Q6A (1999) Specifications: Test Procedures and Acceptance

Criteria for New Drug Substances and New Drug Products: Chemical Substances. International Council for Harmonisation Secretariat. https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf

[17] ICH Harmonised Guideline M4Q(R1) (2003) Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality. International Council for Harmonisation Secretariat. https://www.ich.org/page/ctd

[18] ICH Harmonised Guideline M7(R2) (2023) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. International Council for Harmonisation Secretariat. https://database.ich.org/sites/default/files/ICH_M7%28R2%29_Guideline_Step4_2023_0216_0.pdf

[19] Blessy, M., Patel, R.D., Prajapati, P.N. and Agrawal, Y.K. (2014) Development of Forced Degradation and Stability Indicating Studies of Drugs—A Review. *Journal of Pharmaceutical Analysis*, **4**, 159-165. https://doi.org/10.1016/j.jpha.2013.09.003

[20] Jain, D. and Basniwal, P.K. (2013) Forced Degradation and Impurity Profiling: Recent Trends in Analytical Perspectives. *Journal of Pharmaceutical and Biomedical Analysis*, **86**, 11-35. https://doi.org/10.1016/j.jpba.2013.07.013

[21] Alvarenga Junior, B.R. and Carneiro, R.L. (2019) Chemometrics Approaches in Forced Degradation Studies of Pharmaceutical Drugs. *Molecules*, **24**, Article No. 3804. https://doi.org/10.3390/molecules24203804

[22] Jahani, M., Fazly Bazzaz, B.S., Akaberi, M., Rajabi, O. and Hadizadeh, F. (2023) Recent Progresses in Analytical Perspectives of Degradation Studies and Impurity Profiling in Pharmaceutical Developments: An Updated Review. *Critical Reviews in Analytical Chemistry*, **53**, 1094-1115. https://doi.org/10.1080/10408347.2021.2008226

[23] Görög, S. (2006) The Importance and the Challenges of Impurity Profiling in Modern Pharmaceutical Analysis. *TrAC Trends in Analytical Chemistry*, **25**, 755-757. https://doi.org/10.1016/j.trac.2006.05.011

[24] Alsante, K., Ando, A., Brown, R., Ensing, J., Hatajik, T., Kong, W., *et al.* (2007) The Role of Degradant Profiling in Active Pharmaceutical Ingredients and Drug Products. *Advanced Drug Delivery Reviews*, **59**, 29-37. https://doi.org/10.1016/j.addr.2006.10.006

[25] Zaman, B., Hassan, W., Khan, A., Mushtaq, A., Ali, N., Bilal, M., *et al.* (2022) Forced Degradation Studies and Development and Validation of HPLC-UV Method for the Analysis of Velpatasvir Copovidone Solid Dispersion. *Antibiotics*, **11**, Article No. 897. https://doi.org/10.3390/antibiotics11070897

[26] Goguladinne, B.R., Shyamala, P. and Rao, K.M.V.N. (2025) Forced Degradation Studies of Dobutamine and Isolation, Identification, and Characterization of Potential Degradation Impurity by Preparative HPLC, LC-MS/MS. Development and Validation of Stability Indicative UPLC Method. *Biomedical Chromatography*, **39**, e70211. https://doi.org/10.1002/bmc.70211

[27] Hotha, K.K., Roychowdhury, S. and Subramanian, V. (2016) Drug-Excipient Interactions: Case Studies and Overview of Drug Degradation Pathways. *American Journal of Analytical Chemistry*, **7**, 107-140. https://doi.org/10.4236/ajac.2016.71011

[28] Pimpre, K., Chaganti, S., Khemchandani, R., Pilli, P., Kommalapati, H. and Samanthula, G. (2025) Integrative Study on Triclabendazole Stability: Forced Degradation and *in Silico* Toxicity Prediction of Degradation Products. *Biomedical Chromatography*, **40**, e70331. https://doi.org/10.1002/bmc.70331

[29] Waterman, K.C., Adami, R.C., Alsante, K.M., Antipas, A.S., Arenson, D.R., Carrier, R., *et al.* (2002) Hydrolysis in Pharmaceutical Formulations. *Pharmaceutical Development and Technology*, **7**, 113-146. https://doi.org/10.1081/pdt-120003494

[30] Hovorka, S.W. and Schöneich, C. (2001) Oxidative Degradation of Pharmaceuticals: Theory, Mechanisms and Inhibition. *Journal of Pharmaceutical Sciences*, **90**, 253-269. https://doi.org/10.1002/1520-6017(200103)90:3<253::aid-jps1>3.0.co;2-w

[31] Scott, B.S., Zhang, K., Yehl, P.M. and Yang, S.H. (2024) A Strategic Approach towards Mass Balance Investigations in Pharmaceutical Drug Substance Release Testing: A Peculiar Out of Specification Case Study Encountered during API Manufacture. *Journal of Pharmaceutical and Biomedical Analysis*, **238**, Article ID: 115773. https://doi.org/10.1016/j.jpba.2023.115773

[32] Storme, M.L., Frijlink, H.W. and Vromans, H. (2024) Mass Balance Analysis for Therapeutic Peptides: Case Studies, Applications, and Perspectives. *Journal of Pharmaceutical and Biomedical Analysis*, **251**, Article ID: 116459.

[33] USP General Chapter <1225> (2024) Validation of Compendial Procedures. United States Pharmacopeia-NF.

[34] USP General Chapter <621> (2024) Chromatography. United States Pharmacopeia-NF.

[35] Singh, N., Bansal, P., Maithani, M. and Chauhan, Y. (2020) Development and Validation of a Novel Stability-Indicating RP-HPLC Method for Simultaneous Determination of Tezacaftor and Ivacaftor in Fixed Dose Combination. *Journal of Chromatographic Science*, **58**, 346-354. https://doi.org/10.1093/chromsci/bmz120

[36] Sangani, M.B. and Patel, N. (2024) An Eco-Friendly RP-HPLC Method Development and Validation for Quantification of Favipiravir in Bulk and Tablet Dosage Form Followed by Forced Degradation Study. *Journal of Chromatographic Science*, **62**, 432-438. https://doi.org/10.1093/chromsci/bmad093

[37] Patel, P., Hotha, K.K., Patel, D., Kamma, J., Gudimella, A., Bompelliwar, S., *et al.* (2020) Forced Degradation Studies on Sodium Picosulfate and Separation of 15 Process Related Impurities/Degradants by HPLC. *American Journal of Analytical Chemistry*, **11**, 363-375. https://doi.org/10.4236/ajac.2020.1111029

[38] Pawar, R., Tivari, S., Panchani, D. and Makasana, J. (2024) A Stability-Indicating Method Development and Validation for the Determination of Related Substances in Novel Synthetic Decapeptide by HPLC. *Journal of Peptide Science*, **30**, e3610. https://doi.org/10.1002/psc.3610

[39] O'Neill, R., Yoo, O., Burcham, P., Nguyen, M. and Lim, L.Y. (2025) Development and Validation of a Stability-Indicating RP-HPLC Method for Edaravone Quantification. *Molecules*, **30**, Article No. 2866. https://doi.org/10.3390/molecules30132866

[40] Kowalska, M., Woźniak, M., Kijek, M., Mitrosz, P., Szakiel, J. and Turek, P. (2022) Management of Validation of HPLC Method for Determination of Acetylsalicylic Acid Impurities in a New Pharmaceutical Product. *Scientific Reports*, **12**, Article No. 1. https://doi.org/10.1038/s41598-021-99269-x

[41] Habib, A., Mabrouk, M.M., Fekry, M. and Mansour, F.R. (2022) Glycerol as a New Mobile Phase Modifier for Green Liquid Chromatographic Determination of Ascorbic Acid and Glutathione in Pharmaceutical Tablets. *Journal of Pharmaceutical and Biomedical Analysis*, **219**, Article ID: 114870. https://doi.org/10.1016/j.jpba.2022.114870

[42] EL-Malla, S.F., Mansour, F.R., Elbastawissy, A.B.B. and Elagamy, S.H. (2024) Development of a Stability Indicating High-Performance Liquid Chromatography Method for Determination of Cenobamate: Study of Basic Degradation Kinetics. *BMC Chemistry*, **18**, Article No. 98. https://doi.org/10.1186/s13065-024-01177-4

[43] Bakshi, M. and Singh, S. (2002) Development of Validated Stability-Indicating Assay Methods—Critical Review. *Journal of Pharmaceutical and Biomedical Analysis*, **28**,

1011-1040. https://doi.org/10.1016/s0731-7085(02)00047-x

[44] Rozet, E., Ceccato, A., Hubert, C., Ziemons, E., Oprean, R., Rudaz, S., *et al.* (2007) Analysis of Recent Pharmaceutical Regulatory Documents on Analytical Method Validation. *Journal of Chromatography A*, **1158**, 111-125. https://doi.org/10.1016/j.chroma.2007.03.111

[45] Green, J.M. (1996) Peer Reviewed: A Practical Guide to Analytical Method Validation. *Analytical Chemistry*, **68**, 305A-309A. https://doi.org/10.1021/ac961912f

[46] Taverniers, I., De Loose, M. and Van Bockstaele, E. (2004) Trends in Quality in the Analytical Laboratory. II. Analytical Method Validation and Quality Assurance. *TrAC Trends in Analytical Chemistry*, **23**, 535-552. https://doi.org/10.1016/j.trac.2004.04.001

[47] Waterman, K.C. and Adami, R.C. (2005) Accelerated Aging: Prediction of Chemical Stability of Pharmaceuticals. *International Journal of Pharmaceutics*, **293**, 101-125. https://doi.org/10.1016/j.ijpharm.2004.12.013

[48] Eberle, M., Wasylenko, J.T., Kostelac, D., Kiehna, S., Schellinger, A., Zhang, Z., *et al.* (2025) A Modern Framework for Analytical Procedure Development and Lifecycle Management Based on ICH Q14 Principles. *Analytical Chemistry*, **97**, 12-21. https://doi.org/10.1021/acs.analchem.4c04521

[49] Cassidy, B., Bloomingdale, T. and Carmody, J. (2025) Navigating ICH Q2 (R2) Compliance in Analytical Method Validation: A Gap Analysis Toolkit to Streamline Risk Assessment and Change Management. *Journal of Pharmaceutical Sciences*, **114**, Article ID: 103749. https://doi.org/10.1016/j.xphs.2025.103749

[50] Kirkpatrick, D., Gupta, N., Gopalaswamy, R., Kolhatkar, R., Hudson-Davis, M. and Keire, D. (2025) The Role of Enhanced Analytical Procedure Development in Facilitating Post-Approval Changes via Established Conditions. *The AAPS Journal*, **27**, Article No. 56. https://doi.org/10.1208/s12248-025-01037-6

[51] Borman, P., Campa, C., Delpierre, G., Hook, E., Jackson, P., Kelley, W., *et al.* (2022) Selection of Analytical Technology and Development of Analytical Procedures Using the Analytical Target Profile. *Analytical Chemistry*, **94**, 559-570. https://doi.org/10.1021/acs.analchem.1c03854

[52] Kovačić, J., Amidžić Klarić, D., Turk, N., Krznarić, Ž., Riordan, E. and Mornar, A. (2025) The Stability-Indicating UHPLC-DAD-MS/MS Method Applied for the Forced Degradation Study of Ritlecitinib: An Appraisal of Green and Blue Metrics. *Pharmaceuticals*, **18**, Article No. 124. https://doi.org/10.3390/ph18010124

[53] Mehta, L., Naved, T., Grover, P., Bhardwaj, M. and Mukherjee, D. (2021) LC and LC-MS/MS Studies for Identification and Characterization of New Degradation Products of Ibrutinib and Elucidation of Their Degradation Pathway. *Journal of Pharmaceutical and Biomedical Analysis*, **194**, Article ID: 113768. https://doi.org/10.1016/j.jpba.2020.113768

[54] Grover, P., Bhardwaj, M. and Mukherjee, D. (2022) Identification and Characterization of Forced Degradation Products of Sertraline Hydrochloride Using UPLC, UHPLC-Q-TOF/MS/MS and NMR. *Journal of Pharmaceutical and Biomedical Analysis*, **221**, Article ID: 115045. https://doi.org/10.1016/j.jpba.2022.115045

[55] Modini, A.K., Ranga, M., Puppala, U., Kaliyapermal, M., Geereddy, M.K.R., Samineni, R., *et al.* (2023) Identification, Isolation, and Structural Characterization of Novel Forced Degradation Products of Darunavir Using Advanced Analytical Techniques Like UPLC-MS, Prep-Hplc, HRMS, NMR, and FT-IR Spectroscopy. *Chromatographia*, **86**, 63-78. https://doi.org/10.1007/s10337-022-04226-z

[56] Chakkar, A., Chaturvedi, S., Rajput, N., Sengupta, P. and Sharma, N. (2024) LC/Q-

TOF-MS-Based Structural Characterization of Enasidenib Degradation Products and Establishment of a Stability-indicating Assay Method: Insights into Chemical Stability. *Rapid Communications in Mass Spectrometry*, **38**, e9696. https://doi.org/10.1002/rcm.9696

[57] Jain, M. and Khan, S. (2024) Identification and Characterization of Two New Oxidation Degradation Impurities in Cinnarizine through LC-HRMS/MS and ^{1}H NMR, along with *in Silico* Toxicity Predictions of Its Degradation Products. *Biomedical Chromatography*, **38**, e6013. https://doi.org/10.1002/bmc.6013

[58] Liana, A., Hałuszczuk, A., Gawor, A. and Bulska, E. (2024) Identification and Structural Characterization of Degradation Products of Linagliptin by Mass Spectrometry Techniques. *International Journal of Molecular Sciences*, **25**, Article No. 2591. https://doi.org/10.3390/ijms25052591

[59] Bhatt, N., Sonaje, D., Golla, V.M., Khemchandani, R., K. R, R., Gupta, A.K., *et al.* (2025) Identification and Characterization of Forced Degradation Products of Lumateperone Tosylate by LC-HRMS, GC-MS, NMR, and *in Silico* Toxicity Prediction. *Journal of Pharmaceutical and Biomedical Analysis Open*, **6**, Article ID: 100085. https://doi.org/10.1016/j.jpbao.2025.100085

[60] ANVISA (2015) Resolution of the Collegiate Board RDC No. 53 of December 4, 2015: Requirements for Forced Degradation Studies for Drug Registration or Post-Registration. Agência Nacional de Vigilância Sanitária. https://www.gov.br/anvisa/

[61] ANVISA (2015) Guide for Obtaining Degradation Profile and Identification and Qualification of Degradation Products in Drug Products. Guide No. 04/2015. Agência Nacional de Vigilância Sanitária. https://www.gov.br/anvisa/

[62] PMDA (2023) Q2(R2)/Q14 Summary and Japanese Pharmacopoeia (JP) Perspective. Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/files/000270489.pdf

[63] Japanese Pharmacopoeia, 18th Edition (2021) Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/english/rs-sb-std/standards-development/jp/0029.html

[64] Shah, D., Movaliya, V., Kharidia, S. and Zaveri, M. (2024) Comparative Study of Analytical Method Validation and Process Validation Parameters as per ICH, EMA, WHO and ASEAN Guidelines. *International Journal of Drug Regulatory Affairs*, **12**, 58-64. https://doi.org/10.22270/ijdra.v12i2.675

[65] WHO (2018) Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. WHO Technical Report Series No. 1010, Annex 10. World Health Organization.

[66] Dangy-Caye, A., Mousset, A., Kermad, A., Bouché-Bazerolle, L., Bujar, M., De Lucia, M., *et al.* (2025) Harmonizing Health: A Global Analysis of Pharmaceutical Regulatory Activities by International Regulatory Organizations. *Frontiers in Medicine*, **12**, Article 1636269. https://doi.org/10.3389/fmed.2025.1636269

[67] FDA (2015) Analytical Procedures and Methods Validation for Drugs and Biologics. https://r.search.yahoo.com/_ylt=AwriqozVI2JqPAIAWkoPxQt.;_ylu=Y29sbwNiZjEEcG9zAzEEdnRpZA-MEc2VjA3Ny/RV=2/RE=1786026198/RO=10/RU=https%3a%2f%2fwww.fda.gov%2ffiles%2fdrugs%2fpublished%2fAnalytical-Procedures-and-Methods-Validation-for-Drugs-and-Biologics.pdf/RK=2/RS=J5cDE8zXB4Ln0uC5HU35iow8NIE-

[68] EMA (2023) Guideline on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products. European Medicines Agency.

https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products_en.pdf

[69] Shaik, R.B., Padala, S.K.R., Samsonu, D., DeviII, D.R., Basavaiah, K. and Rao, B.M. (2025) LC-MS/MS Profiling of Stress-Induced Degradation Products of Avapritinib and Development of a Stability-Indicating HPLC Method for Its Quantification and Impurity Analysis. *Methods and Objects of Chemical Analysis*, **20**, 52-58. https://doi.org/10.17721/moca.2025.52-58

[70] Shaik, R.B., Devi, D.R., Basavaiah, K. and Rao, B.M. (2025) Isolation, LC-MS/MS, NMR Characterization, *in Silico* Toxicity, and ADME Evaluation of Stress-Degradation Products of Sunitinib with Optimized Stability-Indicating HPLC Method for Quantification of Sunitinib and Its Impurities. *Separation Science Plus*, **8**, e70001. https://doi.org/10.1002/sscp.70001